AlisonSchecterMD
Cardiology • Newton, MAAdjunct Associate Professor, Medicine - Cardiology, Icahn School of Medicine at Mount Sinai
Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
33 Manor House Road
Newton, MA 02459Phone+1 617-417-8648
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Cardiovascular Disease, 1994 - 1996
Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
State University of New York Downstate Medical Center College of MedicineClass of 1990
Certifications & Licensure
MA State Medical License 2008 - 2026- MA State Medical License 1993 - 2024
Awards, Honors, & Recognition
- Fellow (FCCP) American College Chest Physicians, 2008-2010, 2020
- Fellow (FACC) American College of Cardiology
Publications & Presentations
PubMed
- 76 citationsArterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intoleranceRobin P. Choudhury, Jacqueline Birks, Venkatesh Mani, Luca Biasiolli, Matthew D. Robson
Journal of the American College of Cardiology. 2016-10-18 - 32 citationsNa+/Ca2+ exchanger-1 protects against systolic failure in the Akitains2 model of diabetic cardiomyopathy via a CXCR4/NF-κB pathway.Thomas J. LaRocca, Frank Fabris, Jiqiu Chen, Daniel Benhayon, Shihong Zhang
American Journal of Physiology. Heart and Circulatory Physiology. 2012-08-01 - 106 citationsHepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activationFeng Hong, Ana C. Tuyama, Ting Fang Lee, Johnny Loke, Ritu Agarwal
Hepatology. 2009-06-01
Press Mentions
Predicting Long COVID: Who’s at Risk?March 6th, 2022- AXA1125 – a New Mitochondrial Enhancer Is Being Trialed in Long COVIDNovember 5th, 2021
- Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVIDOctober 26th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
